{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:27:40Z","timestamp":1767374860920,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.oret.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T04:14:46Z","timestamp":1638504886000},"page":"1181-1186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Alphabet Soup"],"prefix":"10.1016","volume":"5","author":[{"given":"Victor M.","family":"Villegas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy G.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2021.09.008_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/1758835921992989","article-title":"Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm","volume":"13","author":"Shahzad","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.oret.2021.09.008_bib2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.oret.2021.09.008_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.oret.2021.06.001","article-title":"Clinical and morphologic characteristics of ERK inhibitor-associated retinopathy","volume":"5","author":"Francis","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oret.2021.09.008_bib4","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2021.09.008_bib5","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.17634","article-title":"Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions","volume":"8","author":"Fu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.oret.2021.09.008_bib6","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.oret.2021.09.008_bib7","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ejca.2013.10.016","article-title":"Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review","volume":"50","author":"Huillard","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.oret.2021.09.008_bib8","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2217\/fon-2018-0608","article-title":"Ocular and orbital side effects of ALK inhibitors: a review article","volume":"15","author":"Chelala","year":"2019","journal-title":"Future Oncol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021002955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653021002955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:29:43Z","timestamp":1762853383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653021002955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2468653021002955"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2021.09.008","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alphabet Soup","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2021.06.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}